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CONCLUSIONS: Recent updates on burden of disease estimates were used and
utilities included but due to the absence of trial data still a number of assumptions
were used. The outcomes of this modeling exercise show that a vaccine against
RSV might be cost-effective, but trial data are warranted.
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OBJECTIVES:To compare cost-effectiveness of tenofovir and other AN in treatment
of adults with CHB in Poland. METHODS: Analysis was performed from the public
payer perspective. A lifetime Marcov model (3-month cycle) was developed defin-
ing heath states based on HBV_DNA level. Following events were included: com-
plications (liver cirrhosis, hepatocellular carcinoma), drug resistance and relapse
after remission. Analysis was performed in total population (regardless of the
HBeAg status) and in subpopulation of HBeAg() patients. Analysis for HBeAg(-)
patients was impossible to conduct due to lack of effectiveness data. Effectiveness
parameters were based on MTC conducted in systematic review of randomized
clinical trials. In the analysis following costs were included: antiviral drugs, mon-
itoring, hospitalization and CHB complications treatment. The reliability of the
estimates was examined by sensitivity analyses of model parameters. RESULTS: In
total population the estimated lifetime QALY per patient were: 12.33 for tenofovir,
11.32 for entecavir and 11.64 for adefovir. The estimated differences in QALYs
between tenofovir and comparators were: 1.00 in comparison to entecavir and 0.69
in comparison to adefovir. The differences were not statistically significant. Aver-
age lifetime costs per patient were: 223,519 PLN for tenofovir, 358,565 PLN for en-
tecavir and 349,535 PLN for adefovir. The resulting difference in costs between
tenofovir and comparators were: -135,045 PLN in comparison to entecavir and
-126,016 PLN in comparison to adefovir. The results for HBeAg() subpopulation
were close to results for total population. CONCLUSIONS: Both in total population,
as well as in HBeAg() subpopulation, tenofovir dominates adefovir and entecavir,
which means that it allows for greater health effects (QALY, LYG) with lower costs
of treatment. Results of probabilistic sensitivity analysis indicates that tenofovir
therapy is cost-effective (for the assumed threshold of three GDP: 102,045 PLN) with
a probability of ca 82% when compared with adefovir and ca 86% in comparison to
entecavir.
PIN80
COST-EFFECTIVENESS OF VACCINATING CHILDREN AGED 2-17 YEARS WITH
INTRANASAL LIVE ATTENUATED INFLUENZA VACCINE (LAIV) IN GERMANY
Damm O1, Rose MA2, Greiner W3, Knuf M4, Wahn U5, Krüger H6, Wutzler P7, Schaberg T8,
Ruf B9, Liese JG10, Eichner M11
1School of Public Health, University of Bielefeld, Bielefeld, Germany, 2Children’s and Adolescents’
Hospital, Goethe University, Frankfurt, Germany, 3Herescon GmbH, Hannover, Germany,
4Children‘s Hospital, Dr. Horst Schmidt Klinik, Wiesbaden, Germany, 5Children’s Hospital,
Charité, Berlin, Germany, 6AstraZeneca GmbH, Wedel, Germany, 7Jena University Hospital,
Friedrich-Schiller University, Jena, Germany, 8Deakoness-Hospital, Rotenburg, Germany,
9Klinikum St. Georg, Leipzig, Germany, 10University Children’s Hospital, Würzburg, Germany,
11Epimos geoInfoNet UG, Tübingen, Germany
OBJECTIVES: In 2011, intranasal administrated live-attenuated influenza vaccine
(LAIV) for prophylaxis of seasonal influenza was approved in the EU for children
aged 2-17 years. Our objective was to estimate the potential epidemiological impact
and cost-effectiveness of the current policy to vaccinate people over 60 years and
people with underlying chronic conditions with trivalent inactivated vaccine (TIV)
compared to the addition of routine childhood vaccination with LAIV in Germany.
METHODS: A compartmental susceptible-exposed-infectious-recovered-suscepti-
ble (SEIRS) model populated with German specific data was developed to explore
the impact of vaccination on the transmission dynamics of seasonal influenza. In
addition, a decision tree was constructed to incorporate several consequences of
influenza infections and to compare costs and outcomes of different vaccination
strategies in the German health care setting. The time horizon was set to ten years
after the introduction of LAIV, assuming childhood vaccination coverage of 70%.
Input data were based on published literature or were derived by expert consulting
using the Delphi technique. RESULTS: Under base-case assumptions, annual rou-
tine vaccination of children would prevent 8.8 million influenza illnesses, resulting
in a reduction of 273,124 cases of acute otitis media and 68,102 cases of community-
acquired pneumonia over ten years if left undiscounted. The discounted incremen-
tal cost-effectiveness ratio was €9601 per QALY gained from a third-party payer
perspective, when compared to the current strategy of vaccinating only risk groups
with TIV. Inclusion of patient co-payments and indirect costs resulted in a dis-
counted 10-year cost-saving to society of €1.16 billion. CONCLUSIONS: Compared
with the current vaccination policy, introducing childhood and adolescent vacci-
nation with LAIV can substantially increase benefits and reduce overall costs when
adopting a societal perspective. Using the commonly cited threshold of €50,000 per
QALY gained, routine vaccination of children with LAIV can be considered cost-
effective from a third-party payer perspective.
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OBJECTIVES: This study aims to evaluate the cost-effectiveness of peg-interferon
alpha-2a plus ribavirin compared with conventional interferon alpha-2a plus riba-
virin for the treatment of chronic hepatitis C (CHC) in China. METHODS: A Markov
health-state model was designed to estimate the direct medical costs and out-
comes (life year gained and quality adjusted life year, QALY) of treating CHC. The
model consists of 7 health states: cured (sustained virological response), CHC, com-
pensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, liver
transplant, and death. Based on literature research, a two-round expert panel sur-
vey was conducted among experienced clinicians nationally in China to identify
medical cost and clinical efficacy data. The evaluation was conducted from a per-
spective of China’s health insurance system to compare combination therapy sce-
narios of peg-interferon alfa-2a (40KD) plus ribavirin with conventional interferon
alfa-2a plus ribavirin. The evolution of a cohort of CHC patients was simulated
along 40 years with yearly cycles. A discounting rate at 3% was used to discount
utilities and medical costs happened at different years. A univariate sensitivity
analysis was performed to understand the key drivers and general sensitivity of the
model. RESULTS: The model showed that peg-interferon alpha-2a scenario could
prolong 2.25 (30.02 years vs. 27.77 years) total life years compared with conven-
tional interferon alpha-2a scenario. The discounted QALYs generated by peg-inter-
feron were 2.19 longer than that of conventional interferon (18.58 QALYs vs. 16.39
QALYs). The discounted mean total cost per patient treated with peg-interferon
alpha-2a scenario was 114,751 CNY (US$17,930), and 130,047 CNY (US$20,320) for
patient treated with conventional interferon. CONCLUSIONS: The results of the
model suggest that peg-interferon alfa-2a treatment is dominant in both health
outcomes and long-term treatment costs compared with conventional interferon
alpha-2a for the treatment of CHC, which means peg-interferon alfa-2a treatment
can generate cost savings for the China’s health insurance system.
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OBJECTIVES: Atazanavir/r (ATV/r) and darunavir/r (DRV/r) are commonly used to
suppress HIV in Germany. Compared to lopinavir/r, both have demonstrated sim-
ilar relative efficacy in randomized clinical trials (RCT) in previously untreated
patients; whereas annual drug acquisition costs are 250 euro more for DRV/r. How-
ever, the objective was to estimate how these would translate into costs and ef-
fects, after 5 and 25 years. METHODS: The cost-effectiveness was forecasted using
a microsimulation-model (monthly cycles) for previously untreated HIV-patients
Response to medication was modeled as a reduction in HIV-RNA viral-load. In
accordance with literature, increase in CD4 could persist up to 5 years while
having a response; whereas no response resulted in the opposite. The occurrences
of AIDS defining events and non-AIDS defining malignancies were linked to the
current CD4 and independent of therapy. Adverse events (AE) on the other hand
were treatment-specific and the following were considered: 1) diarrhea; 2) dizzi-
ness; 3) jaundice; 4) nausea; and 5) rash. Toxicities associated with the long-term
use of agents considered in the model included: 1) cardiovascular events; 2) renal
insufficiency; and 3) hepatic failure. Drug efficacy and AE incidences were based on
published RCTs - compared via an indirect comparison - whereas, other data was
based on published literature. RESULTS: After 5 years, initiation with ATV/r use
was found to be associated with a lower total cost compared to DRV/r. In the
long-term (i.e. 25 year time horizon) the use of ATV/r was found to be associated
with an increase in survival of 16.0 (discounted) years; 0.31 life years and 0.55
QALYs compared to DRV/r. This resulted in an ICUR of € 11,241 per QALY gained.
Results were most sensitive to changes in virological parameters, market shares for
future lines and cost per CD4-level. CONCLUSIONS: The model forecasts ATV/r to
be cost-effective compared to DRV/r in Germany.
PIN83
COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF 200 DAYS
PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) INFECTIONS IN HIGH RISK (D/
R-) KIDNEY TRANSPLANT RECIPIENTS IN POLAND
Kawalec P1, Holko P2, Boratynska M3, Glyda M4, Ignacak E5, Russel-Szymczyk M6,
Szkultecka-Sebek M6, Kaweczynska-Lason A6
1Jagiellonian University, Kraków , Poland, 2Centrum HTA, Cracow, Poland, 3Wroclaw Medical
University, Wroclaw, Poland, 4District Hospital, Poznan, Poland, 5University Hospital in Cracov,
Cracow, Poland, 6Roche Polska Sp. z o.o., Warsaw, Poland
OBJECTIVES: To assess cost-effectiveness of CMV disease prophylaxis prolonga-
tion in kidney transplant recipients from 110 to 200 days from Polish public payer’s
perspective. METHODS: Clinical efficacy and safety of prolonged to 200 days pro-
phylaxis of CMV disease in kidney transplant recipients (D/R-) was assessed in
systematic review. Following measurable differential direct medical costs were
estimated and included: costs of drugs and diagnostic, hospital/ambulatory proce-
dures, adverse events treatment, acute rejection, CMV disease treatment, oppor-
tunistic infections treatment, hemodialysis and subsequent kidney transplanta-
tion. Cost data were gathered in 4 medical centers. Markov model was used to
calculate costs and efficacy in 23.5 years time horizon - the maximum expected
survival of kidney transplant recipient. Costs and clinical effects were discounted
(5% for costs and effects, 0% for costs and effects, 5% for costs and 0% for effects).
Probabilistic, one-way, multiway sensitivity analyses were conducted. RESULTS:
The prolongation to 200 days of CMV disease prophylaxis in kidney transplant
recipients is lined to reduction in frequency of CMV infections, acute transplant
rejections, loss of graft functions and need of subsequent kidney transplantation.
In the 23.5 years gain of 0.3846 life years and 0.3178 quality adjusted life years can
A280 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
